Skip to main content
SpringerLink
Log in

Gliomas

  • Chapter
Molecular Pathology in Clinical Practice

  • 3536 Accesses

Abstract

Many advances have been made in evaluating the molecular genetics of gliomas. For example, the presence of 1p and 19q deletions is associated with gliomas of oligodendroglial lineage, with oligodendrogliomas that have a better survival, and with oligodendrogliomas that respond to chemotherapy and radiation therapy. While prospective data are needed to confirm these associations, 1p and 19q deletion testing has become a part of routine neurooncology practice. Alterations of chromosome 10, EGFR, PTEN, IDH1, MGMT, ATRX, and TP53 are associated with different grades of astrocytic gliomas and with patient survival. While their clinical utility requires further investigation, these markers (and others) will be increasingly used to stratify patients to current and new therapeutic approaches. In the future, it is likely that the survival rate of primary gliomas will be lengthened using molecularly targeted therapies.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 89.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 119.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Gittleman HR, Ostrom QT, Rouse CD, Dowling JA, et al. Trends in central nervous system tumor incidence relative to other common cancers in adults, adolescents, and children in the United States, 2000 to 2010. Cancer. 2015;121:102–12.

    Article  PubMed Central  PubMed  Google Scholar 

  2. Jemal A, Murray T, Samuels A, Ghafoor A, Ward E, Thun MJ. Cancer statistics. CA Cancer J Clin. 2003;53:5–26.

    Article  PubMed  Google Scholar 

  3. Louis DN, Ohgaki H, Wiestler OD, Cavenee WK. WHO classification of tumors of the central nervous system. Lyon, France: IARC Press; 2007.

    Google Scholar 

  4. Kleihues P, Ohgaki H. Primary and secondary glioblastomas: from concept to clinical diagnosis. Neuro-oncol. 1999;1:44–51.

    PubMed Central  CAS  PubMed  Google Scholar 

  5. Smith JS, Wang XY, Qian J, et al. Amplification of the platelet-derived growth factor receptor-A (PDGFRA) gene occurs in oligodendrogliomas with grade IV anaplastic features. J Neuropathol Exp Neurol. 2000;59:495–503.

    Article  CAS  PubMed  Google Scholar 

  6. Louis DN, Perry A, Burger P, et al. International Society of neuropathology—Haarlem consensus guidelines for nervous system tumor classification and grading. Brain Pathol. 2014;5:429–35.

    Article  Google Scholar 

  7. Jansen M, Yip S, Louis DN. Molecular pathology in adult gliomas: diagnostic, prognostic, and predictive markers. Lancet Neurol. 2010;9:717–26.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  8. Kitange GJ, Smith JS, Jenkins RB. Genetic alterations and chemotherapeutic response in human diffuse gliomas. Expert Rev Anticancer Ther. 2001;1:595–605.

    Article  CAS  PubMed  Google Scholar 

  9. Lin H, Bondy ML, Langford LA, et al. Allelic deletion analyses of MMAC/PTEN and DMBT1 loci in gliomas: relationship to prognostic significance. Clin Cancer Res. 1998;4:2447–54.

    CAS  PubMed  Google Scholar 

  10. Smith JS, Tachibana I, Passe SM, et al. PTEN mutation, EGFR amplification, and outcome in patients with anaplastic astrocytoma and glioblastoma multiforme. J Natl Cancer Inst. 2001;93:1246–56.

    Article  CAS  PubMed  Google Scholar 

  11. Tada K, Shiraishi S, Kamiryo T, et al. Analysis of loss of heterozygosity on chromosome 10 in patient with malignant astrocytic tumors: correlation with patient age and survival. J Neurosurg. 2001;95:651–9.

    Article  CAS  PubMed  Google Scholar 

  12. Rasheed A, Herndon JE, Stenzel TT, et al. Molecular markers of prognosis in astrocytic tumors. Cancer. 2002;94:2688–97.

    Article  CAS  PubMed  Google Scholar 

  13. Terada K, Tamiya T, Daido S, et al. Prognostic value of loss of heterozygosity around three candidate tumor suppressor genes on chromosome 10q in astrocytomas. J Neurooncol. 2002;58:107–14.

    Article  PubMed  Google Scholar 

  14. Cairncross G, Macdonald D, Ludwin S, et al. Chemotherapy for anaplastic oligodendroglioma. National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol. 1994;12:2013–21.

    CAS  PubMed  Google Scholar 

  15. Smith JS, Alderete B, Minn Y, et al. Localization of common deletion regions on 1p and 19q in human gliomas and their association with histological subtype. Oncogene. 1999;18:4144–52.

    Article  CAS  PubMed  Google Scholar 

  16. Mueller W, Hartmann C, Hoffmann A, et al. Genetic signature of oligoastrocytomas correlates with tumor location and denotes distinct molecular subsets. Am J Pathol. 2002;161:313–9.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  17. Cairncross JG, Ueki K, Zlatescu MC, et al. Specific genetic predictors of chemotherapeutic response and survival in patients with anaplastic oligodendrogliomas. J Natl Cancer Inst. 1998;90:1473–9.

    Article  CAS  PubMed  Google Scholar 

  18. Smith J, Perry A, Borell T, et al. Alterations of chromosome arms 1p and 19q as predictors of survival in oligodendrogliomas, astrocytomas, and mixed oligoastrocytomas. J Clin Oncol. 2000;18:636–45.

    CAS  PubMed  Google Scholar 

  19. Kouwenhoven MC, Kros JM, French PJ, et al. 1p/19q loss within oligodendroglioma is predictive for response to first line temozolomide but not to salvage treatment. Eur J Cancer. 2006;42:2499–503.

    Article  CAS  PubMed  Google Scholar 

  20. Yan H, Parsons DW, Jin G, et al. IDH1 and IDH2 mutations in gliomas. N Engl J Med. 2009;360:765–73.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  21. Sasaki H, Zlatescu MC, Betensky RA, Ino Y, Cairncross JG, Louis DN. PTEN is a target of chromosome 10q loss in anaplastic oligodendrogliomas and PTEN alterations are associated with poor prognosis. Am J Pathol. 2001;159:359–67.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  22. Sanson M, Leuraud P, Aguirre-Cruz L, et al. Analysis of loss of chromosome 10q, DMBT1 homozygous deletions, and PTEN mutations in oligodendrogliomas. J Neurosurg. 2002;97:1397–401.

    Article  CAS  PubMed  Google Scholar 

  23. Hegi ME, Diserens AC, Gorlia T, et al. MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med. 2005;352:997–1003.

    Article  CAS  PubMed  Google Scholar 

  24. Frederick L, Wang XY, Eley G, James CD. Diversity and frequency of epidermal growth factor receptor mutations in human glioblastomas. Cancer Res. 2000;60:1383–7.

    CAS  PubMed  Google Scholar 

  25. Feldkamp MM, Roncari L, Lau N, Salhia B, Guha A. Expression of EGFRvIII is a better prognostic marker for GBM than either EGFR expression or the Ki-67 labeling index. Neuro-oncol. 2002;4:343.

    Google Scholar 

  26. Hartmann C, Meyer J, Balss J, et al. Type and frequency of IDH1 and IDH2 mutations are related to astrocytic and oligodendroglial differentiation and age: a study of 1,010 diffuse gliomas. Acta Neuropathol. 2009;118:469–74.

    Article  PubMed  Google Scholar 

  27. Capper D, Weissert S, Balss J, et al. Characterization of R132H mutation-specific IDH1 antibody binding in brain tumors. Brain Pathol. 2009;20:245–54.

    Article  PubMed  Google Scholar 

  28. Simmons ML, Lamborn KR, Takahashi M, et al. Analysis of complex relationships between age, p53, epidermal growth factor receptor, and survival in glioblastoma patients. Cancer Res. 2001;61:1122–8.

    CAS  PubMed  Google Scholar 

  29. Peraud A, Watanabe K, Schwechheimer K, Yonekawa Y, Kleihues P, Ohgaki H. Genetic profile of the giant cell glioblastoma. Lab Invest. 1999;79:123–9.

    CAS  PubMed  Google Scholar 

  30. Kosel S, Scheithauer BW, Graeber MB. Genotype-phenotype correlation in gemistocytic astrocytomas. Neurosurgery. 2001;48:187–93.

    Article  CAS  PubMed  Google Scholar 

  31. Nieder C, Petersen S, Petersen C, Thames HD. The challenge of p53 as prognostic and predictive factor in gliomas. Cancer Treat Rev. 2000;26:67–73.

    Article  CAS  PubMed  Google Scholar 

  32. Kraus JA, Glesmann N, Beck M, et al. Molecular analysis of the PTEN, TP53 and CDKN2A tumor suppressor genes in long-term survivors of glioblastoma multiforme. J Neurooncol. 2000;48:89–94.

    Article  CAS  PubMed  Google Scholar 

  33. Kraus JA, Wenghoefer M, Glesmann N, et al. TP53 gene mutations, nuclear p53 accumulation, expression of Waf/p21, Bcl-2, and CD95 (APO-1/Fas) proteins are not prognostic factors in de novo glioblastoma multiforme. J Neurooncol. 2001;52:263–72.

    Article  CAS  PubMed  Google Scholar 

  34. Shiraishi S, Tada K, Nakamura H, et al. Influence of p53 mutations on prognosis of patients with glioblastoma. Cancer. 2002;95:249–57.

    Article  CAS  PubMed  Google Scholar 

  35. Wiestler B, Capper D, Holland-Letz T, et al. ATRX loss defines the classification of anaplastic gliomas and identifies a subgroup of IDH mutant astrocytic tumors with better prognosis. Acta Neuropathol. 2013;126:443–51.

    Article  CAS  PubMed  Google Scholar 

  36. Randazzo L, Scarpace L, Lemke N, et al. Tumoral and chromosomal heterogeneity in oligodendrogliomas detected with medium-throughput 1p/19q LOH analysis. Neuro-oncol. 2002;4:346.

    Google Scholar 

  37. Bigner SH, Mark J, Burger PC, et al. Specific chromosomal abnormalities in malignant human gliomas. Cancer Res. 1988;48:405–11.

    CAS  PubMed  Google Scholar 

  38. Nigro JM, Takahashi MA, Ginzinger DG, et al. Detection of 1p and 19q loss in oligodendroglioma by quantitative microsatellite analysis, a real-time quantitative polymerase chain reaction assay. Am J Pathol. 2001;158:1253–62.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  39. Ohman L, Gedda L, Hesselager G, et al. A new antibody recognizing the vIII mutation of human epidermal growth factor receptor. Tumour Biol. 2002;23:61–9.

    Article  PubMed  Google Scholar 

  40. Watson MA, Perry A, Budhjara V, Hicks C, Shannon WD, Rich KM. Gene expression profiling with oligonucleotide microarrays distinguishes World Health Organization grade of oligodendrogliomas. Cancer Res. 2001;61:1825–9.

    CAS  PubMed  Google Scholar 

  41. Mischel PS, Shai R, Choe GY, et al. Identification of distinctive subtypes of primary glioblastoma multiforme by gene expression profiling. Neuro-oncol. 2002;4:330.

    Google Scholar 

  42. Nutt CL, Mani DR, Betensky RA, et al. An accurate microarray class prediction model for high grade gliomas. Neuro-oncol. 2002;4:345.

    Google Scholar 

  43. Misra A, Pellarin M, Moore D, et al. A high-resolution genome wide map of genetic aberrations in human astrocytoma. Neuro-oncol. 2002;4:330.

    Google Scholar 

  44. Brennan C, Kim H, Cauwels C, et al. Identification of candidate genetic alterations from array-CGH in human glioblastomas. Neuro-oncol. 2002;4:327.

    Google Scholar 

  45. Lal A, Glazer CA, Martinson HM, et al. Mutant epidermal growth factor receptor up-regulates molecular effectors of tumor invasion. Cancer Res. 2002;62:3335–9.

    CAS  PubMed  Google Scholar 

  46. Sausville EA, Elsayed Y, Monga M, Kim G. Signal transduction-directed cancer treatments. Annu Rev Pharmacol Toxicol. 2003;43:199–231.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Anatomic Pathology, Pathology and Laboratory Medicine, Weill Cornell Medical College, 525 E. 68th St., Starr 1043, New York, NY, 10065, USA

    Ehud Lavi M.D.

Authors
  1. Ehud Lavi M.D.
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Ehud Lavi M.D. .

Editor information

Editors and Affiliations

  1. Pathology and Laboratory Medicine, University of Vermont College of Medicine and University of Vermont Medical Center, Burlington, Vermont, USA

    Debra G.B. Leonard

Rights and permissions

Reprints and permissions

Copyright information

© 2016 Springer International Publishing Switzerland

About this chapter

Cite this chapter

Lavi, E. (2016). Gliomas. In: Leonard, D. (eds) Molecular Pathology in Clinical Practice. Springer, Cham. https://doi.org/10.1007/978-3-319-19674-9_38

Download citation

  • DOI: https://doi.org/10.1007/978-3-319-19674-9_38

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-319-19673-2

  • Online ISBN: 978-3-319-19674-9

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation